A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder

Stephen Bent, Kiah Bertoglio, Paul Ashwood, Alan Bostrom, Robert L. Hendren

Research output: Contribution to journalArticle

75 Citations (Scopus)

Abstract

We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.

Original languageEnglish (US)
Pages (from-to)545-554
Number of pages10
JournalJournal of Autism and Developmental Disorders
Volume41
Issue number5
DOIs
StatePublished - May 2011

Fingerprint

Omega-3 Fatty Acids
Randomized Controlled Trials
Checklist
Sample Size
Fatty Acids
Placebos
Safety
Therapeutics
Autism Spectrum Disorder

Keywords

  • Autism
  • Clinical trial
  • Complementary and alternative medicine
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Developmental and Educational Psychology

Cite this

A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. / Bent, Stephen; Bertoglio, Kiah; Ashwood, Paul; Bostrom, Alan; Hendren, Robert L.

In: Journal of Autism and Developmental Disorders, Vol. 41, No. 5, 05.2011, p. 545-554.

Research output: Contribution to journalArticle

Bent, Stephen ; Bertoglio, Kiah ; Ashwood, Paul ; Bostrom, Alan ; Hendren, Robert L. / A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder. In: Journal of Autism and Developmental Disorders. 2011 ; Vol. 41, No. 5. pp. 545-554.
@article{8cb9051826af42108042b215ad2f07c9,
title = "A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder",
abstract = "We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.",
keywords = "Autism, Clinical trial, Complementary and alternative medicine, Omega-3 fatty acids",
author = "Stephen Bent and Kiah Bertoglio and Paul Ashwood and Alan Bostrom and Hendren, {Robert L.}",
year = "2011",
month = "5",
doi = "10.1007/s10803-010-1078-8",
language = "English (US)",
volume = "41",
pages = "545--554",
journal = "Journal of Autism and Developmental Disorders",
issn = "0162-3257",
publisher = "Springer New York",
number = "5",

}

TY - JOUR

T1 - A pilot randomized controlled trial of omega-3 fatty acids for autism spectrum disorder

AU - Bent, Stephen

AU - Bertoglio, Kiah

AU - Ashwood, Paul

AU - Bostrom, Alan

AU - Hendren, Robert L.

PY - 2011/5

Y1 - 2011/5

N2 - We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.

AB - We conducted a pilot randomized controlled trial to determine the feasibility and initial safety and efficacy of omega-3 fatty acids (1.3 g/day) for the treatment of hyperactivity in 27 children ages 3-8 with autism spectrum disorder (ASD). After 12 weeks, hyperactivity, as measured by the Aberrant Behavior Checklist, improved 2.7 (±4.8) points in the omega-3 group compared to 0.3 (±7.2) points in the placebo group (p = 0.40; effect size = 0.38). Correlations were found between decreases in five fatty acid levels and decreases in hyperactivity, and the treatment was well tolerated. Although this pilot study did not find a statistically significant benefit from omega-3 fatty acids, the small sample size does not rule out small to moderate beneficial effects.

KW - Autism

KW - Clinical trial

KW - Complementary and alternative medicine

KW - Omega-3 fatty acids

UR - http://www.scopus.com/inward/record.url?scp=79955677328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955677328&partnerID=8YFLogxK

U2 - 10.1007/s10803-010-1078-8

DO - 10.1007/s10803-010-1078-8

M3 - Article

C2 - 20683766

AN - SCOPUS:79955677328

VL - 41

SP - 545

EP - 554

JO - Journal of Autism and Developmental Disorders

JF - Journal of Autism and Developmental Disorders

SN - 0162-3257

IS - 5

ER -